Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 7:3:309.
doi: 10.3389/fgene.2012.00309. eCollection 2012.

Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia

Gabriele Stocco  1 , Raffaella Franca, Federico Verzegnassi, Margherita Londero, Marco Rabusin, Giuliana Decorti
Affiliations

Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia

Gabriele Stocco et al. Front Genet. .

Abstract

Multilocus genotypes have been shown to be of relevance for using pharmacogenomic principles to individualize drug therapy. As it relates to thiopurine therapy, genetic polymorphisms of TPMT are strongly associated with the pharmacokinetics and clinical effects of thiopurines (mercaptopurine and azathioprine), influencing their toxicity and efficacy. We have recently demonstrated that TPMT and ITPA genotypes constitute a multilocus genotype of pharmacogenetic relevance for children with acute lymphoblastic leukemia (ALL) receiving thiopurine therapy. The use of high-throughput genomic analysis allows identification of additional candidate genetic factors associated with pharmacogenetic phenotypes, such as TPMT enzymatic activity: PACSIN2 polymorphisms have been identified by a genome-wide analysis, combining evaluation of polymorphisms and gene expression, as a significant determinant of TPMT activity in the HapMap CEU cell lines and the effects of PACSIN2 on TPMT activity and mercaptopurine induced adverse effects were confirmed in children with ALL. Combination of genetic factors of relevance for thiopurine metabolizing enzyme activity, based on the growing understanding of their association with drug metabolism and efficacy, is particularly promising for patients with pediatric ALL. The knowledge basis and clinical applications for multilocus genotypes of importance for therapy with mercaptopurine in pediatric ALL is discussed in the present review.

Keywords: ITPA; PACSIN2; TPMT; acute lymphoblastic leukemia; mercaptopurine; multilocus genotypes; pharmacogenetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Barplot reporting the percentage of patients developing severe (Grade 3–4) GI toxicity during consolidation therapy in patients with ALL treated according to the St Jude Total 13B protocol as a function of TPMT rs1142345 / SLCO1B1 rs11045879 / PACSIN2 rs2413739 multilocus genotype (Stocco et al., 2012).
See this image and copyright information in PMC

References

    1. Adam de Beaumais T., Dervieux T., Fakhoury M., Medard Y., Azougagh S., Zhang D., et al. (2010). The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 66, 653–658 10.1007/s00280-009-1205-4 - DOI - PubMed
    1. Advani S., Pai S., Venzon D., Adde M., Kurkure P. K., Nair C. N., et al. (1999). Acute lymphoblastic leukemia in India: an analysis of prognostic factors using a single treatment regimen. Ann. Oncol. 10, 167–176 10.1023/A:1008366814109 - DOI - PubMed
    1. Cheok M. H., Evans W. E. (2006). Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6, 117–129 10.1038/nrc1800 - DOI - PubMed
    1. Consortium C. P. I. (2012). Clinical Pharmacogenetics Implementation Consortium (CPIC) Gene-drug pairs [Online]. Available at: http://www.pharmgkb.org/page/cpicGeneDrugPairs [accessed Oct 22, 2012].
    1. Conter V., Bartram C. R., Valsecchi M. G., Schrauder A., Panzer-Grumayer R., Moricke A., et al. (2010). Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206–3214 10.1182/blood-2009-10-248146 - DOI - PubMed